A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times

Therapeutic Drug Monitoring

Volumn 31, Issue 5, 2009, Pages 579-584

  Wang, Yanfeng ^a   Chia, Yen Lin ^b   Nedelman, Jerry ^b   Schran, Horst ^a   Mahon, Francois Xavier ^c   Molimard, Mathieu ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Modeling and Simulation/Statistics ^*

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic myeloid leukemia; Gastrointestinal stromal tumor; Imatinib; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

IMATINIB;

ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CHRONIC MYELOID LEUKEMIA; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SIMULATION;

ALGORITHMS; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 70349655281     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181b2c8cf     Document Type: Article

References (21)

1. Morton JM, Williamson S, Kear LM, et al. Therapeutic drug monitoring of prednisolone after lung transplantation. J Heart Lung Transplant. 2006; 25:557-563.
2. Spector R, Park GD, Johnson GF, et al. Therapeutic drug monitoring. Clin Pharmacol Ther. 1988;43:345-353. (Pubitemid 18112812)
3. Alnaim L. Therapeutic drug monitoring of cancer chemotherapy. J Oncol Pharm Pract. 2007;13:207-221.
4. Lennard L. Therapeutic drug monitoring of cytotoxic drugs. Br J Clin Pharmacol. 2001;52(Suppl 1):75S-87S.
5. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108: 1809-1820.
6. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355:2408-2417.
7. Savage DG, Antman KH. Imatinib mesylate-A new oral targeted therapy. N Engl J Med. 2002;346:683-693.
8. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-4349.
9. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466-1478.
10. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standarddose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496-3499.
11. Larson RA, Druker BJ, Guilhot FA, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: A subanalysis of the IRIS study. Blood. 2008;111:4022-4028.
12. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels correlate with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27:3141-3147.
13. White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007;110:4064-4072.
14. Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003; 101:2368-2373.
15. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI- 571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.
16. Crossman LC, O'Brien SG. Imatinib therapy in chronic myeloid leukemia. Hematol Oncol Clin North Am. 2004;18:605-617, viii.
17. Schmidli H, Peng B, Riviere GJ, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: Results of a phase III study. Br J Clin Pharmacol. 2005;60: 35-44.
18. Widmer N, Decosterd LA, Csajka C, et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol. 2006;62:97-112. (Pubitemid 44195246)
19. Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: A retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol. 2005;55:379-386.
20. Delbaldo C, Chatelut E, Re M, et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res. 2006;12(20 Pt 1):6073-6078.
21. Schmidli H, Peng B. Update of the population analysis (including all PK samples analyzed till 27-Jul-2002). Novartis internal document. 2002.